Supernus Pharmaceuticals (Nasdaq: SUPN) marked the five-year anniversary of the FDA approval of Qelbree (viloxazine extended-release capsules) for attention-deficit/hyperactivity disorder ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA